Thermo Fisher ScientificTMOEarnings & Financial Report
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006.
TMO Q1 FY2026 Key Financial Metrics
Revenue
$11.0B
Gross Profit
N/A
Operating Profit
$1.9B
Net Profit
$1.7B
Gross Margin
N/A
Operating Margin
16.9%
Net Margin
15.0%
YoY Growth
6.2%
EPS
$4.43
Thermo Fisher Scientific Q1 FY2026 Financial Summary
Thermo Fisher Scientific reported revenue of $11.0B (up 6.2% YoY) for Q1 FY2026, with a net profit of $1.7B (up 9.6% YoY) (15.0% margin).
Key Financial Metrics
| Total Revenue | $11.0B |
|---|---|
| Net Profit | $1.7B |
| Gross Margin | N/A |
| Operating Margin | 16.9% |
| Report Period | Q1 FY2026 |
Revenue Breakdown
Thermo Fisher Scientific Q1 FY2026 revenue of $11.0B breaks down across 4 segments, led by Laboratory Products and Biopharma Services at $6.0B (54.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Laboratory Products and Biopharma Services | $6.0B | 54.8% |
| Life Sciences Solutions | $2.6B | 24.0% |
| Analytical Instruments | $1.7B | 15.6% |
| Specialty Diagnostics | $1.1B | 10.4% |
Thermo Fisher Scientific Annual Revenue by Year
Thermo Fisher Scientific annual revenue history includes year-by-year totals (for example, 2025 revenue was $44.6B).
Thermo Fisher Scientific Quarterly Revenue & Net Profit History
Thermo Fisher Scientific results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $11.0B | +6.2% | $1.7B | 15.0% |
| Q4 FY2025 | $12.2B | +7.2% | $2.0B | 16.1% |
| Q3 FY2025 | $11.1B | +4.9% | $1.6B | 14.5% |
| Q2 FY2025 | $10.9B | +3.0% | $1.6B | 14.9% |
| Q1 FY2025 | $10.4B | +0.2% | $1.5B | 14.6% |
| Q4 FY2024 | $11.4B | +4.7% | $1.8B | 16.0% |
| Q3 FY2024 | $10.6B | +0.2% | $1.6B | 15.4% |
| Q2 FY2024 | $10.5B | -1.6% | $1.5B | 14.7% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.54B | $10.60B | $11.39B | $10.36B | $10.86B | $11.12B | $12.21B | $11.01B |
| YoY Growth | -1.6% | 0.2% | 4.7% | 0.2% | 3.0% | 4.9% | 7.2% | 6.2% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $98.50B | $100.36B | $97.32B | $99.04B | $101.23B | $103.02B | $110.34B | $113.28B |
| Liabilities | $51.06B | $51.37B | $47.74B | $49.65B | $50.72B | $52.00B | $56.94B | $61.34B |
| Equity | $47.43B | $48.99B | $49.58B | $49.39B | $50.51B | $51.02B | $53.41B | $51.94B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $1.96B | $2.17B | $3.29B | $723.0M | $1.40B | $2.24B | $3.46B | $1.19B |